Atuzaginstat, a gingipain inhibitor targeting oral pathogen P. gingivalis, reduced neuropsychiatric symptoms including agitation and disinhibition in P. gingivalis-positive Alzheimer's patients while decreasing caregiver burden. The selective benefit in pathogen-positive subgroups suggests oral-systemic infection may contribute meaningfully to behavioral decline in cognitive disease.
Key Points
- Gingipain inhibitor reduced agitation, aggression, disinhibition in P. gingivalis-positive AD
- 57% slowing of cognitive decline in prespecified P. gingivalis-positive subgroup
- Significant caregiver distress reduction; no benefit in pathogen-negative patients
Longevity Analysis
The stratified response—benefit only in P. gingivalis-positive patients—points to a specific mechanism linking oral microbial burden to neuropsychiatric dysfunction rather than a general neuroprotective effect. This aligns with emerging evidence that periodontal pathology triggers systemic inflammation and crosses the blood-brain barrier, affecting mood regulation and behavioral control. For patients with both cognitive decline and behavioral disturbance, identifying and addressing chronic oral infection represents a concrete intervention that may interrupt a specific disease pathway rather than broadly slowing inevitable decline.
Original published by Longevity.Technology.